{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/non-alcoholic-fatty-liver-disease-nafld/management/management/","result":{"pageContext":{"chapter":{"id":"92480bd7-0484-5fe9-a7bf-d6797adb368e","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field 7e241d41-532a-41bb-b408-14d5437adb34 --><h2>Scenario: Management</h2><!-- end field 7e241d41-532a-41bb-b408-14d5437adb34 -->","summary":"Covers the management of people with suspected or confirmed non-alcoholic fatty liver disease (NAFLD) in primary care, and when to refer.","htmlStringContent":"<!-- begin item 2d5646a6-c23c-4c97-8b95-bcfad4f23433 --><!-- begin field 8b654b35-9792-47d1-be4f-acbc01585fa3 --><p>From age 18 years onwards.</p><!-- end field 8b654b35-9792-47d1-be4f-acbc01585fa3 --><!-- end item 2d5646a6-c23c-4c97-8b95-bcfad4f23433 -->","topic":{"id":"abeafb29-55b4-564c-a734-190ce99b5488","topicId":"284bcb15-d9e5-4fa5-97c5-b12061b64d8d","topicName":"Non-alcoholic fatty liver disease (NAFLD)","slug":"non-alcoholic-fatty-liver-disease-nafld","lastRevised":"Last revised in October 2016","chapters":[{"id":"d0fc610b-a161-5d27-aff1-910d3e6bd6af","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"748ff87f-6f43-5b88-826b-8a67516fdf5f","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4a580b3e-3e5e-50fe-bbe8-63c6a475223b","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"cfdf5ea1-068e-544d-a066-a9e0b5007c65","slug":"changes","fullItemName":"Changes"},{"id":"2d1f70a5-e0ca-56d6-af3c-40bcced1ff70","slug":"update","fullItemName":"Update"}]},{"id":"f6da1f95-da2b-55bd-8bd1-82a26c6e49f3","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2df5bf15-3a0c-550d-b1ae-49c13b980bd2","slug":"goals","fullItemName":"Goals"},{"id":"899d29ba-a633-5852-b88b-1e12f2e583a0","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"98a2b07c-cb2b-5bf6-8758-a1ffcef6d2b8","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"567377f9-5d4b-58d2-961d-c67f47aa67b3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"20b1d2c6-1aab-5c3c-8560-98f485589680","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"bde5c853-d1bc-5612-b254-6de06cef5bca","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"271f684c-2115-5009-831e-20aa4e06a952","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"9d30a3cc-c4cb-5049-8a58-68e8628c259e","slug":"definition","fullItemName":"Definition"},{"id":"66b72646-5ad1-5d7a-91e0-65e06d4da026","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9a5c1fa8-bae7-517a-beac-7470da445796","slug":"causes","fullItemName":"Causes"},{"id":"c1592142-fe7a-537c-8d46-2d3836ae5625","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"5f220e0c-e0b7-5332-a19d-50b80b98f34e","slug":"complications","fullItemName":"Complications"},{"id":"ad47e9ed-f83a-51bb-874e-85ea1a9756c3","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"2755df5f-b687-58d9-9f7c-96df41230049","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"9faeeb6d-9870-5bd7-bfd4-35cfd840ff5b","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"e0b64459-7125-5764-b029-3c2c2d770254","slug":"assessment","fullItemName":"Assessment"}]},{"id":"df1d3ccc-4b69-5415-bf4d-b81e66c90d85","fullItemName":"Management","slug":"management","subChapters":[{"id":"92480bd7-0484-5fe9-a7bf-d6797adb368e","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"2c7f01d1-e8b6-5b31-8c34-b4e6ecd555e8","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"00b0d6bf-28e1-5673-b966-4dd5bbb035cc","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"e3a16505-5916-56fe-b828-251f23afd363","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"753add0e-0bf6-59e4-b5a7-e46df0904d4c","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"f6942026-4d74-5fbd-bb79-1aae8f3b4576","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c2dffddc-29cb-5918-ad31-69cdb772fa22","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"47354e90-5f65-5a83-b670-29798add860f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c12b3b71-cdfd-532e-a293-8cd38e7b7b1e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"df1d3ccc-4b69-5415-bf4d-b81e66c90d85","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"e4013de1-eb41-5512-9b75-9557e53a42e4","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field 722a6d7b-89a2-469b-b3d5-af2d5d05e2b1 --><h3>How should I manage NAFLD in primary care?</h3><!-- end field 722a6d7b-89a2-469b-b3d5-af2d5d05e2b1 -->","summary":null,"htmlStringContent":"<!-- begin item 7461a89b-894d-4ee7-9fcb-4b0fc36d5070 --><!-- begin field 758fefc8-3f8d-43aa-8934-5906a1b78d13 --><p><strong>Manage a person with a working diagnosis of non-alcoholic fatty liver disease (NAFLD) in primary care if <a class=\"topic-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/background-information/causes/\">other causes</a> of liver disease have been excluded, and there is a low risk of <a class=\"topic-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/diagnosis/assessment/\">advanced liver fibrosis</a>.</strong></p><ul><li>Advise the person that there is currently no specific drug treatment licensed for the management of NAFLD, but the aim of management is to reduce the risk of progression of NAFLD, and to reduce the risks of cardiac and liver-related morbidity and mortality.</li><li>Give lifestyle modification advice on diet, physical activity, and regular exercise to all people with NAFLD, and encourage gradual sustained weight loss, especially if a person is overweight or <a class=\"topic-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/background-information/risk-factors/\">obese</a>.<ul><li>A recommended target of 10% weight loss over 6 months may be helpful.</li><li>Be aware that rapid weight loss, for example due to a very low calorie diet, should be avoided due to the risk of worsening liver inflammation and fibrosis.</li><li>See the sections on lifestyle advice in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a> and <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a> for more information.</li></ul></li><li>Advise on drinking alcohol within national recommended limits. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/alcohol-problem-drinking/\">Alcohol - problem drinking</a> for more information.</li><li>Ensure that associated conditions such as hypertension, hyperlipidaemia, and type 2 diabetes mellitus are optimally managed. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-not-diabetic/\">Hypertension - not diabetic</a>, <a class=\"topic-reference external-reference\" href=\"/topics/lipid-modification-cvd-prevention/\">Lipid modification - CVD prevention</a> and <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a> for more information.<ul><li>Be aware that people with NAFLD do not have any additional risks of hepatotoxicity if prescribed statin drug treatment, and people already taking statins should continue to take them as prescribed.</li></ul></li><li>Provide advice on sources of information and support for people with NAFLD, such as the <a href=\"http://www.britishlivertrust.org.uk/publications/download-publications/\" data-hyperlink-id=\"b0ae10c6-dcd9-4c49-a815-a98d01514c19\">British Liver Trust</a> which has a patient guide on <a href=\"http://www.britishlivertrust.org.uk/wp-content/uploads/NAFLD.pdf\" data-hyperlink-id=\"96e28552-7cc6-4bd2-a63d-a98d01514efb\">Non-alcoholic fatty liver disease</a>. The National Institute for Health and Care Excellence (NICE, available at <a href=\"https://www.nice.org.uk/\" data-hyperlink-id=\"eb221983-48a9-48b0-afe5-a98d01514f09\">www.nice.org.uk</a>) also provides a patient information leaflet on <a href=\"https://www.nice.org.uk/guidance/ng49/resources/nonalcoholic-fatty-liver-disease-nafld-assessment-and-management-3300305986501\" data-hyperlink-id=\"10729927-bac8-4c09-8e15-a98d01514f31\">Non-alcoholic fatty liver disease (NAFLD): assessment and management</a>.</li></ul><!-- end field 758fefc8-3f8d-43aa-8934-5906a1b78d13 --><!-- end item 7461a89b-894d-4ee7-9fcb-4b0fc36d5070 -->","subChapters":[{"id":"4f3937ac-c7c1-512e-a4bd-e6ed0a2b4141","slug":"basis-for-recommendation-a19","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 4fd13985-abc6-4f6e-b7c7-6d685d65d762 --><h4>Basis for recommendation</h4><!-- end field 4fd13985-abc6-4f6e-b7c7-6d685d65d762 -->","summary":null,"htmlStringContent":"<!-- begin item a19d43ca-c94c-4121-a328-678f99d24f2c --><!-- begin field 966f9cd5-f3be-47fb-9647-4c6199ea8e16 --><p>The recommendations on how to manage a person with suspected non-alcoholic fatty liver disease (NAFLD) in primary care are largely based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Non-alcoholic fatty liver disease: assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">NICE, 2016</a>], the World Gastroenterology Organisation Global Guidelines <em>Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis</em>, which are based on selected position statements and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">World Gastroenterology Organisation, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">World Gastroenterology Organisation, 2014</a>]; expert opinion and a literature review in the American Association for the Study of Liver Diseases practice guideline <em>The diagnosis and management of non-alcoholic fatty liver disease </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Chalasani et al, 2012</a>]; and two European Association of the Study of the Liver (EASL) publications <em>Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Thomas et al, 2012</a>] and <em>EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">EASL-EASD-EASO, 2016</a>]. In addition, expert opinion in a regional clinical guideline <em>Guidelines for management of adults with asymptomatic liver function abnormalities </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Hudson and McPherson, 2014</a>] and in review articles on NAFLD [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Adams et al, 2005</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Dyson et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Sattar et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Dyson et al, 2015</a>] support the recommendations on management.</p><h5>Weight loss advice</h5><ul><li>The recommendations on weight loss are based on the NICE guideline which states that there is some evidence that exercise reduces liver fat content, and weight loss achieved as part of a lifestyle modification strategy in adults with NAFLD appears to reduce the risk of NAFLD progression [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">NICE, 2016</a>].<ul><li>The benefits of lifestyle modification for the minority of people with NAFLD who are not overweight or obese (about 5% of the NAFLD population) are likely to be smaller [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">NICE, 2016</a>].</li></ul></li><li>European and global guidelines state that gradual weight loss improves insulin sensitivity [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Thomas et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">World Gastroenterology Organisation, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">EASL-EASD-EASO, 2016</a>], and a gradual 5–10% weight loss has been shown to improve hepatic steatosis on histology and liver enzyme profiles, but not fibrosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">World Gastroenterology Organisation, 2012</a>].<ul><li>An EASL systematic review of 23 prospective studies evaluating the effect of diet and/or exercise interventions found consistent reductions in hepatic steatosis and/or liver aminotransferase concentrations, with the most marked improvements correlating with the degree of associated weight loss. It however noted marked heterogeneity in study design, definitions of disease, methods of assessment, and interventions used across the studies [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Thomas et al, 2012</a>].</li></ul></li><li>The suggested recommended target weight loss of 10% over 6 months is based on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Adams et al, 2005</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Dyson et al, 2015</a>] and a regional clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Hudson and McPherson, 2014</a>].</li></ul><h5>Advice on alcohol</h5><ul><li>The advice on drinking alcohol within national recommended limits is based on the NICE guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">NICE, 2016</a>].</li><li>The EASL clinical guideline found no evidence to currently recommend abstinence from alcohol for people with NAFLD, and states drinking alcohol in moderation 'might even be protective against NAFLD, NASH and fibrosis as compared with total abstinence' [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">EASL-EASD-EASO, 2016</a>].</li></ul><h5>Managing associated conditions</h5><ul><li>The recommendations on managing metabolic risk factors and associated conditions is widely cited in the literature, and it has been noted that the risk of non-alcoholic steatohepatitis (NASH) increases with the number of metabolic risk factors a person has [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Dyson et al, 2014</a>]. The NICE guideline also notes that people who are overweight or obese, or have type 2 diabetes, are at increased risk of progressive disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">NICE, 2016</a>].</li></ul><!-- end field 966f9cd5-f3be-47fb-9647-4c6199ea8e16 --><!-- end item a19d43ca-c94c-4121-a328-678f99d24f2c -->","subChapters":[]}]},{"id":"db0b389f-fe32-5e95-9d9c-a27615bf55a3","slug":"referral","fullItemName":"Referral","depth":3,"htmlHeader":"<!-- begin field e4dcfe9d-28f4-4dbc-ab88-f58b10c03f55 --><h3>When should I refer a person with NAFLD?</h3><!-- end field e4dcfe9d-28f4-4dbc-ab88-f58b10c03f55 -->","summary":null,"htmlStringContent":"<!-- begin item 17515d11-69c0-4b95-b1fc-1a7227597a64 --><!-- begin field 2846b4d3-8fe1-4164-aad8-5d0d779d4178 --><ul><li>Refer a person with suspected or confirmed non-alcoholic fatty liver disease (NAFLD) to a hepatology specialist for further <a class=\"topic-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/management/management/#specialist-investigations-management\">assessment and management</a>, if:<ul><li>The person is at <a class=\"topic-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/diagnosis/assessment/\">high risk</a> of advanced liver fibrosis.</li><li>There are signs of <a class=\"topic-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/diagnosis/assessment/\">advanced liver disease</a> on examination.</li><li>There is uncertainty about the diagnosis.</li></ul></li></ul><!-- end field 2846b4d3-8fe1-4164-aad8-5d0d779d4178 --><!-- end item 17515d11-69c0-4b95-b1fc-1a7227597a64 -->","subChapters":[{"id":"0c4dd256-f2ba-574b-89b8-485f6dbfbaad","slug":"specialist-investigations-management","fullItemName":"Specialist investigations and management","depth":4,"htmlHeader":"<!-- begin field c6d1583d-d66d-42ca-bcfd-f97169e28db6 --><h4>Specialist investigations and management</h4><!-- end field c6d1583d-d66d-42ca-bcfd-f97169e28db6 -->","summary":null,"htmlStringContent":"<!-- begin item a76dc82d-37bd-4320-a426-d1b79f962a85 --><!-- begin field 5d237d1f-634b-4e12-8393-a9de40935323 --><p><strong>Specialist investigations may include:</strong></p><ul><li><strong>Transient elastography (fibroscan)</strong><ul><li>Fibrotic livers have reduced elasticity, and transient elastography is a non-invasive test which measures liver stiffness, which correlates with the degree of liver fibrosis.</li></ul></li><li><strong>Liver biopsy</strong><ul><li>Liver biopsy may be needed to confirm the diagnosis of non-alcoholic steatohepatitis (NASH) or cirrhosis, exclude other liver disease, and decide on the need for further management and monitoring in secondary care. It also may be needed where non-invasive tests for the evaluation of liver disease severity suggest advanced fibrosis, or indeterminate or discordant results.</li><li>It can assess the degree of hepatic steatosis, hepatocellular injury, inflammation, and fibrosis, and provides both diagnostic and prognostic information on liver fibrosis and the potential for progression.</li><li>It is an expensive and invasive procedure with a risk of morbidity and rarely mortality, with the potential for sampling errors, and is dependent on the interpretation of histopathology results.</li></ul></li></ul><p><strong>Specialist management may include:</strong></p><ul><li><strong>Monitoring of people with advanced liver disease</strong><ul><li>Surveillance programmes to monitor for hepatocellular cancer (HCC), for example using ultrasound scans and alpha-fetoprotein serum monitoring.</li></ul></li><li><strong>Drug treatments</strong><ul><li>In secondary or tertiary care, pioglitazone or vitamin E drug treatment may be considered (off-label indication) for adults with advanced liver fibrosis.</li></ul></li><li><strong>Liver transplantation</strong><ul><li>The World Gastroenterology Organisation reports that 30–40% of people with NASH-related cirrhosis require liver transplantation. NASH cirrhosis accounted for 12% of people listed for liver transplantation in the UK in 2009, and non-alcoholic fatty liver disease (NAFLD) is the second leading indication for HCC-related liver transplantation in the USA.</li><li>NASH may recur after liver transplantation.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Adams et al, 2005</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Chalasani et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">World Gastroenterology Organisation, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Dyson et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Sattar et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">World Gastroenterology Organisation, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">European Association for the Study of the Liver, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">EASL-EASD-EASO, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">NICE, 2016</a>]</p><!-- end field 5d237d1f-634b-4e12-8393-a9de40935323 --><!-- end item a76dc82d-37bd-4320-a426-d1b79f962a85 -->","subChapters":[]},{"id":"b17ca7fc-45ca-503c-b897-65ef995e8483","slug":"basis-for-recommendation-a88","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 044b074a-65ca-4aa2-95b6-9b5430d7f081 --><h4>Basis for recommendation</h4><!-- end field 044b074a-65ca-4aa2-95b6-9b5430d7f081 -->","summary":null,"htmlStringContent":"<!-- begin item a88efd7f-9aaa-49eb-b948-0d8719ef691c --><!-- begin field ce469020-1cc7-49e3-9d47-2678591f700e --><p>The recommendations on when to refer a person with non-alcoholic fatty liver disease (NAFLD) are based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Non-alcoholic fatty liver disease (NAFLD): assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">NICE, 2016</a>], the European Association for the Study of the Liver <em>EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">EASL-EASD-EASO, 2016</a>], the World Gastroenterology Organisation Global Guideline <em>Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis</em>, which is based on selected position statements and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">World Gastroenterology Organisation, 2014</a>], expert opinion and a literature review in the American Association for the Study of Liver Diseases practice guideline <em>The diagnosis and management of non-alcoholic fatty liver disease </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Chalasani et al, 2012</a>], and a review article in the British Medical Journal (BMJ) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Sattar et al, 2014</a>].</p><ul><li>The EASL and NICE clinical guidelines highlight that the specialist treatment of non-alcoholic steatohepatitis (NASH) should reduce the risk of progression to liver fibrosis and advanced liver disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">EASL-EASD-EASO, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">NICE, 2016</a>].</li></ul><!-- end field ce469020-1cc7-49e3-9d47-2678591f700e --><!-- end item a88efd7f-9aaa-49eb-b948-0d8719ef691c -->","subChapters":[]}]},{"id":"336ebfb3-d725-5280-9cdf-d23ca4563e2c","slug":"follow-up","fullItemName":"Follow up","depth":3,"htmlHeader":"<!-- begin field f576abde-5317-4470-9c52-fa83e5ce0323 --><h3>How should I follow up a person with NAFLD in primary care?</h3><!-- end field f576abde-5317-4470-9c52-fa83e5ce0323 -->","summary":null,"htmlStringContent":"<!-- begin item 72263803-8044-4fb4-9c2f-d22474a64149 --><!-- begin field 20c132b3-e6f9-4dde-8db2-cababaf56489 --><p><strong>Ensure a person with non-alcoholic fatty liver disease (NAFLD) and a low risk of advanced liver fibrosis is reviewed in primary care annually, depending on clinical judgement.</strong></p><ul><li><strong>Examine the person to check:</strong><ul><li>For signs of <a class=\"topic-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/diagnosis/assessment/\">advanced liver disease</a>, that may indicate progression of NAFLD.</li><li>Blood pressure to assess for hypertension. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-not-diabetic/\">Hypertension - not diabetic</a> for more information.</li><li>Weight and body mass index (BMI) — to assess for obesity and the impact of any diet and exercise changes on weight loss. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a> for more information.</li></ul></li><li><strong>Arrange blood tests</strong> to assess for metabolic risk factors, and manage accordingly.<ul><li>Renal function tests to assess for chronic kidney disease. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/chronic-kidney-disease/\">Chronic kidney disease</a> for more information.</li><li>HbA1c to assess for impaired glucose regulation and type 2 diabetes. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a> for more information.</li><li>Lipid profile — to assess for hyperlipidaemia. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/lipid-modification-cvd-prevention/\">Lipid modification - CVD prevention</a> for more information.</li></ul></li><li><strong>Reassess the person's r</strong><strong>isk of cardiovascular disease annually </strong>— see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a> for more information.</li><li><strong>Reassess the person's risk of advanced liver fibrosis every 3 years — do not use routine liver blood tests.</strong> See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/diagnosis/assessment/\">Assessment</a> for more information.<ul><li>If the person is at high risk of advanced liver fibrosis, <a class=\"topic-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/management/management/#referral\">refer</a> the person to a hepatology specialist for further <a class=\"topic-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/management/management/#specialist-investigations-management\">assessment and management</a>.</li><li>If the person is at low risk of advanced liver fibrosis, reassess the risk every 3 years, and continue to <a class=\"topic-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/management/management/#management\">manage</a> the person in primary care.</li></ul></li></ul><!-- end field 20c132b3-e6f9-4dde-8db2-cababaf56489 --><!-- end item 72263803-8044-4fb4-9c2f-d22474a64149 -->","subChapters":[{"id":"705c0d6a-d74c-553d-8934-c287f136ccf7","slug":"basis-for-recommendation-283","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 13f789ef-be19-4f10-9ac9-9c70a920a4ba --><h4>Basis for recommendation</h4><!-- end field 13f789ef-be19-4f10-9ac9-9c70a920a4ba -->","summary":null,"htmlStringContent":"<!-- begin item 28371196-b0d6-43db-a248-b58d23fbcdc5 --><!-- begin field 116314a7-132f-4e75-b494-8b429ad89d30 --><p>The recommendations on follow up of a person with non-alcoholic fatty liver disease (NAFLD) in primary care are largely based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Non-alcoholic fatty liver disease (NAFLD): assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">NICE, 2016</a>], the European Association for the Study of the Liver <em>EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">EASL-EASD-EASO, 2016</a>], the World Gastroenterology Organisation Global Guideline <em>Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis</em>, which is based on selected position statements and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">World Gastroenterology Organisation, 2012</a>]; and expert opinion in a regional clinical guideline <em>Guidelines for management of adults with asymptomatic liver function abnormalities </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Hudson and McPherson, 2014</a>], a clinical case review [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Bhala et al, 2009</a>], and a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Dyson et al, 2015</a>].</p><h5>Frequency of primary care review</h5><ul><li>The recommendation that all people with NAFLD should be reviewed in primary care annually is pragmatic, based on what CKS considers to be good medical practice, as people with NAFLD are likely to have additional risk factors for developing cardiovascular disease and metabolic syndrome.</li></ul><h5>Assessing for metabolic risk factors</h5><ul><li>The recommendation on reassessing metabolic risk factors at review is based on the EASL and NICE clinical guidelines, that a worsening metabolic risk factor profile may increase a person's risk of developing non-alcoholic steatohepatitis (NASH) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">EASL-EASD-EASO, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">NICE, 2016</a>]. Specifically, people with type 2 diabetes are at increased risk of more progressive fibrosis in NASH, so it is important that people with NAFLD are regularly screened for diabetes mellitus [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Dyson et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">NICE, 2016</a>].</li></ul><h5>Reassessing risk of cardiovascular disease</h5><ul><li>The importance of reassessing cardiovascular risk is highlighted in the NICE guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">NICE, 2016</a>] and in a regional clinical guideline that states that people with NAFLD are more at risk of cardiovascular morbidity and mortality than liver-related complications [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Hudson and McPherson, 2014</a>].</li></ul><h5>Reassessing risk of advanced liver fibrosis</h5><ul><li>The recommendation on reassessing the risk of advanced liver fibrosis every 3 years for people with a low risk of advanced liver fibrosis is based on expert opinion in the NICE guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">NICE, 2016</a>].<ul><li>NICE found that a shorter frequency for rechecking the risk of advanced liver fibrosis was not cost-effective, even if the person has additional risk factors for progressive liver disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">NICE, 2016</a>].</li><li>NICE recommends against using routine liver blood tests to assess for advanced liver fibrosis. In addition, the World Gastroenterology Organisation highlights that liver function tests (LFTs) may be unreliable in monitoring NAFLD disease progression to NASH. It states that NASH is often under-diagnosed as progressive fibrosis may be present with stable or improving LFT results [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">World Gastroenterology Organisation, 2012</a>].</li></ul></li></ul><!-- end field 116314a7-132f-4e75-b494-8b429ad89d30 --><!-- end item 28371196-b0d6-43db-a248-b58d23fbcdc5 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}